Leaflet MELDONIU PHARMEXON 500mg capsules


Indicated for: cardiac metabolic support

Substance: meldoniu (anti-ischemic metabolic agent)

ATC: C01EB22 (Cardiovascular system | Other cardiac preparations)

Meldonium is a medication used to improve physical performance and treat cardiovascular conditions such as angina and heart failure. It works by optimizing cellular metabolism and increasing oxygen flow to tissues.

The drug is commonly used in Eastern Europe and Central Asia but is not approved for use in many other countries. Meldonium is available in capsule or injectable solution form, and the dosage is adjusted based on the condition being treated.

Although considered safe at therapeutic doses, meldonium may cause side effects such as headaches, dizziness, nausea, or allergic reactions. Its use has been controversial in sports, as it has been banned by the World Anti-Doping Agency (WADA) since 2016.

Patients taking meldonium should be monitored by a doctor, especially if they have other chronic conditions or are taking additional medications. Pregnant or breastfeeding women should avoid using this medication without a specialist's recommendation.

General data about MELDONIU PHARMEXON 500mg

  • Substance: meldoniu
  • Date of last drug list: 01-02-2022
  • Commercial code: W68354002
  • Concentration: 500mg
  • Pharmaceutical form: capsules
  • Quantity: 60
  • Product type: generic
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

  • Manufacturer: AS GRINDEKS - LETONIA
  • Holder: PHARMEXON CONSULTING S.R.O. - REPUBLICA CEHA
  • Number: 14134/2021/02
  • Shelf life: 4 years

Pharmaceutical forms available for meldoniu

Concentrations available for meldoniu

  • 500mg
  • 500mg/5ml